Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

VALN

Valneva SE ADR

Oct 08 • 04:00PM ET

5.84

Dollar change -0.07
Percentage change -1.23	%

Healthcare • Biotechnology • France • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.50	Insider Own	0.38%	Shs Outstand	81.08M	Perf Week	1.17%
Market Cap	473.30M	Forward P/E	-	EPS next Y	-0.84	Insider Trans	0.00%	Shs Float	80.77M	Perf Month	-15.64%
Income	-34.72M	PEG	-	EPS next Q	-0.27	Inst Own	0.81%	Short Float	0.06%	Perf Quarter	-18.92%
Sales	163.00M	P/S	2.90	EPS this Y	94.81%	Inst Trans	24.64%	Short Ratio	4.63	Perf Half Y	-27.41%
Book/sh	2.57	P/B	2.27	EPS next Y	-922.47%	ROA	-6.36%	Short Interest	0.05M	Perf Year	-48.20%
Cash/sh	1.74	P/C	3.36	EPS next 5Y	-	ROE	-17.98%	52W Range	5.63 - 14.49	Perf YTD	-43.70%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-9.17%	52W High	-59.71%	Beta	2.16
Dividend TTM	-	Quick Ratio	2.15	Sales past 5Y	31.63%	Gross Margin	38.55%	52W Low	3.69%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	2.63	EPS Y/Y TTM	-1221.75%	Oper. Margin	-69.74%	RSI (14)	36.69	Volatility	1.40% 2.84%
Employees	676	Debt/Eq	1.26	Sales Y/Y TTM	-53.58%	Profit Margin	-21.30%	Recom	1.20	Target Price	17.83
Option/Short	No / Yes	LT Debt/Eq	1.13	EPS Q/Q	-45.74%	Payout	-	Rel Volume	0.45	Prev Close	5.91
Sales Surprise	-7.41%	EPS Surprise	-0.67%	Sales Q/Q	-6.43%	Earnings	Aug 13 BMO	Avg Volume	11.26K	Price	5.84
SMA20	-4.01%	SMA50	-14.87%	SMA200	-24.80%	Trades		Volume	5,052	Change	-1.23%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-03-22	Initiated	H.C. Wainwright	Buy	$34

Oct-04-24 01:30AM	Valneva SE - Declaration of shares and voting rights - September 30, 2024 (GlobeNewswire)
Oct-03-24 01:00AM	Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET (GlobeNewswire)
Sep-18-24 01:00AM	Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ , to EMA and Health Canada (GlobeNewswire)
Sep-13-24 02:30AM	Valneva Announces the Success of its Private Placement Raising approximately 60 Million (GlobeNewswire) -8.52%
Sep-12-24 04:05PM	Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros (GlobeNewswire)
12:00PM	Loading…
Sep-04-24 12:00PM	VALNEVA - Declaration of shares and voting rights: August 31, 2024 (GlobeNewswire)
Sep-03-24 01:00AM	Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate (GlobeNewswire)
Aug-13-24 01:00AM	Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates (GlobeNewswire) +7.35%
Aug-06-24 02:30AM	VALNEVA - Declaration of shares and voting rights: July 31, 2024 (GlobeNewswire)
Aug-01-24 01:00AM	Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World's Most Clinically Advanced Tetravalent Shigella Vaccine Candidate (GlobeNewswire)
Jul-29-24 03:04PM	3 Promising Biotech Stocks You Can Pick Up for Less Than $10 (InvestorPlace)
Jul-22-24 01:00AM	CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World's First Chikungunya Vaccine (GlobeNewswire)
Jul-17-24 04:00PM	Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion (GlobeNewswire)
Jul-08-24 12:45PM	Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine (Zacks)
Jul-04-24 12:00PM	Declaration of shares and voting rights - Valneva SE - June 30, 2024 (GlobeNewswire)
01:00AM	Loading…
Jul-01-24 01:00AM	Valneva Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, IXCHIQ (GlobeNewswire)
Jun-26-24 11:45AM	Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board (GlobeNewswire)
Jun-24-24 11:27AM	Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval (Zacks) +8.90%
01:00AM	Valneva Announces Health Canada Approval of the World's First Chikungunya Vaccine, IXCHIQ (GlobeNewswire)
Jun-05-24 01:00AM	Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update (GlobeNewswire)
Jun-04-24 12:00PM	VALNEVA - Declaration of shares and voting rights: May 31, 2024 (GlobeNewswire)
11:35AM	Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June (GlobeNewswire)
Jun-03-24 11:35AM	Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases (GlobeNewswire)
May-31-24 11:35AM	Valneva Receives EMA's Positive CHMP Opinion for its Chikungunya Vaccine (GlobeNewswire)
May-21-24 01:00AM	Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer (GlobeNewswire) -7.24%
May-13-24 08:53AM	VALN Stock Earnings: Valneva Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
01:00AM	Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine (GlobeNewswire)
May-07-24 01:00AM	Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
May-06-24 01:30AM	Declaration of shares and voting rights April 30, 2024 - VALNEVA SE (GlobeNewswire)
Apr-04-24 12:00PM	Declaration of voting rights - Valneva SE, March 2024 (GlobeNewswire)
02:00AM	Loading…
Mar-26-24 02:00AM	Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate (GlobeNewswire)
Mar-25-24 02:00AM	Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F (GlobeNewswire)
Mar-21-24 11:06AM	Valneva SE (NASDAQ:VALN) Q4 2023 Earnings Call Transcript (Insider Monkey)
02:00AM	Valneva to Present on its Chikungunya Vaccine IXCHIQ , Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C. (GlobeNewswire)
Mar-20-24 02:00AM	Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook (GlobeNewswire) -10.35%
Mar-18-24 02:00AM	Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed (GlobeNewswire)
Mar-06-24 02:30AM	VALNEVA Declaration of shares and voting rights - February 29, 2024 (GlobeNewswire)
Mar-04-24 01:00AM	Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences (GlobeNewswire)
Feb-29-24 01:00AM	U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ (GlobeNewswire)
Feb-15-24 01:00AM	Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance (GlobeNewswire)
Feb-07-24 02:30AM	VALNEVA: Declaration of shares and voting rights - January 31, 2024 (GlobeNewswire)
Feb-05-24 01:00AM	Valneva Announces Sale of Priority Review Voucher for $103 Million (GlobeNewswire)
Jan-10-24 01:00AM	Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine (GlobeNewswire) -7.01%
Jan-05-24 02:30AM	VALNEVA - Declaration of shares and voting rights: December 31, 2023 (GlobeNewswire)
Jan-04-24 11:45AM	Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum (GlobeNewswire) +5.45%
Dec-29-23 04:30PM	Valneva Provides Updated 2023 Financial Guidance (GlobeNewswire)
Dec-20-23 11:45AM	Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors (GlobeNewswire)
Dec-06-23 02:30AM	VALNEVA Declaration of shares and voting rights - November 30, 2023 (GlobeNewswire)
Dec-04-23 04:20PM	Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15 (GlobeNewswire)
01:00AM	Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ (GlobeNewswire)
Nov-27-23 01:00AM	EMA Accepts Valneva's Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment (GlobeNewswire)
Nov-15-23 01:30AM	Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of Directors (GlobeNewswire)
Nov-13-23 01:00AM	Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate (GlobeNewswire)
Nov-11-23 10:25AM	Valneva SE (NASDAQ:VALN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 01:00AM	Valneva Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ (GlobeNewswire)
Nov-09-23 01:00AM	Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates (GlobeNewswire) +6.67%
Nov-07-23 01:00AM	Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-06-23 02:30AM	VALNEVA Declaration of shares and voting rights: October 31, 2023 (GlobeNewswire)
Oct-25-23 12:15PM	Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment (GlobeNewswire) +6.72%
Oct-11-23 11:45AM	Valneva to Present on Chikungunya at Several Leading Scientific Conferences (GlobeNewswire)
Oct-05-23 02:30AM	VALNEVA - Declaration of shares and voting rights: September 30, 2023 (GlobeNewswire)
Sep-27-23 09:33AM	Valneva SE (NASDAQ:VALN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Sep-25-23 01:00AM	Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million (GlobeNewswire)
Sep-21-23 01:00AM	Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Sep-07-23 01:00AM	Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate (GlobeNewswire)
Sep-06-23 02:30AM	VALNEVA Declaration of shares and voting rights: August 31, 2023 (GlobeNewswire)
Aug-31-23 01:00PM	Valneva to Participate in Investor Conferences in the United States and Europe in September 2023 (GlobeNewswire)
Aug-29-23 01:00AM	Health Canada Accepts Valnevas Chikungunya Vaccine License Application for Review (GlobeNewswire)
Aug-28-23 01:00AM	Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate (GlobeNewswire)
Aug-17-23 01:00AM	Valneva Announces Extension of Existing Loan Agreement (GlobeNewswire)
Aug-14-23 01:00AM	Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate (GlobeNewswire)
Aug-03-23 02:30AM	VALNEVA Declaration of shares and voting rights - July 31, 2023 (GlobeNewswire)
Jul-05-23 02:30AM	VALNEVA - Declaration of shares and voting rights: June 30, 2023 (GlobeNewswire)
Jun-22-23 01:00AM	Valneva Supervisory Board Recommends Transition from a Two-Tier Governance Model to a Board of Directors (GlobeNewswire)
Jun-21-23 12:15PM	Valneva Announces Successful Outcome of its AGM and the Appointment of Pfizers Former Vaccine R&D Head to its Supervisory Board (GlobeNewswire)
Jun-13-23 01:00AM	Valneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The Lancet (GlobeNewswire)
Jun-07-23 02:00AM	VALNEVA - Declaration of shares and voting rights: May 31, 2023 (GlobeNewswire)
May-31-23 01:15AM	Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June (GlobeNewswire)
01:00AM	Valneva Announces the Availability of Documentation for its Shareholder Meeting (GlobeNewswire)
May-30-23 01:00AM	Valneva Files for Chikungunya Vaccine Authorization with Health Canada (GlobeNewswire)
May-04-23 12:00PM	VALNEVA - Declaration of shares and voting rights - April 30, 2023 (GlobeNewswire) +21.84%
01:00AM	Valneva Reports First Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Apr-06-23 02:00AM	VALNEVA - Declaration of shares and voting rights - March 31, 2023 (GlobeNewswire)
Mar-31-23 01:00AM	Valneva Announces Filing of 2022 Universal Registration Document and US Form 20-F (GlobeNewswire)
Mar-30-23 01:00AM	Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C. (GlobeNewswire)
Mar-23-23 02:00AM	Valneva Reports Full Year 2022 Results and Provides Corporate Updates (GlobeNewswire)
Mar-06-23 02:00AM	VALNEVA - Declaration of shares and voting rights - February 28, 2023 (GlobeNewswire)
Mar-02-23 01:00AM	Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001 (GlobeNewswire)
Mar-01-23 11:45AM	Valneva to Present at the Cowen 43rd Annual Healthcare Conference (GlobeNewswire)
Feb-20-23 01:00AM	FDA Accepts Valnevas Chikungunya Vaccine License Application for Priority Review (GlobeNewswire)
Feb-17-23 01:00AM	Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15 (GlobeNewswire) -7.10%
Feb-16-23 01:00AM	Valneva Reports Full Year 2022 Revenue and Cash, Provides First 2023 Guidance (GlobeNewswire) +5.85%
Feb-14-23 01:00AM	Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate (GlobeNewswire)
Feb-03-23 12:00PM	VALNEVA Declaration of shares and voting rights - January 31, 2023 (GlobeNewswire)
Jan-19-23 12:00PM	VALNEVA - Declaration of shares and voting rights: Status on December 31, 2022 (corrected data) and January 4, 2023 (GlobeNewswire)
Jan-05-23 12:00PM	VALNEVA - Declaration of shares and voting rights: December 31, 2022 (GlobeNewswire)
Dec-30-22 12:30PM	Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine (GlobeNewswire)
Dec-23-22 11:04AM	Valneva Concludes FDA Regulatory Submission For One-Shot Chikungunya Vaccine (Benzinga)
02:41AM	Tesla, Meta Platforms, and Valneva rise premarket (Investing.com)
01:00AM	Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Candidate (GlobeNewswire)

Valneva SE is a specialty vaccine company, which focuses on the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases. It operates through the following segments: Commercialized Products, COVID, Vaccine Candidates, and Technologies and Services. The Commercialized Products segment markets vaccines, currently IXIARO and DUKORAL vaccines, as well as third-party products. The COVID segment develops, manufactures, and distribute related to COVID-19 vaccine candidate, VLA2001. The Vaccine Candidates segment focuses on proprietary research and development programs aiming to generate new approvable products to generate future cash flows from product sales or from commercialization through partnering with pharmaceutical companies. The Technologies and Services segment offers services and inventions at a commercialization stage. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VALN

Valneva SE ADR

Upgrade your FINVIZ experience